NR1H4 and hepatocellular carcinoma: The therapeutic exploitation of the intestinal FXR/FGF19 axis activation in cholestasis25 and its translation into protection from HCC development in Abcb4−/− mice19 prompt us to further examine the feasibility of a FGF19-based therapy in chronic liver and intestinal disease.